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Methods: Participants: Antiretroviral naïve adult males with CD4 count ≥350 cells/mm3.
Interventions: Patients were randomised to receive thalidomide 200 mg QD for 3 weeks (Thalidomide group) or
not (Control group) and followed for 48 weeks.
Objective: We hypothesized that short-term Thalidomide use would reduce HIV related inflammation and HIV
replication among antiretroviral naïve HIV infected individuals.
Outcome: Viral loads, CD4/CD8 counts, ultra-sensitive C-reactive protein (US-CRP), cell activation markers, and
plasma lipopolysaccharide (LPS) were analyzed.
Randomisation: Unrestricted randomisation.
Blinding: No blinding was used.
Results: Numbers randomised: Thirty recruited individuals were randomised to Thalidomide (16 patients) or
Control (14 patients) groups.
Recruitment: Patients were recruited from April 2011 to January 2013.
Outcome: Viral loads remained stable in both groups. During thalidomide treatment, a decrease in CD4/CD8 ratio
(p=0.04), a decrease in CD4 count (p=0.04), an increase in cell activation calculated by the percentage of CD38
+/HLA-DR+ CD8 cells (p b 0.05) and an increase in US-CRP (p b 0.01) were observed in the Thalidomide group,
with all parameters returning to baseline levels after thalidomide interruption. We confirmed that thalidomide
increased HIV replication in vitro of 6 of 7 samples from long-term antiretroviral suppressed individuals.
Harms: No class 3/4 adverse events occurred.
Conclusions: Short-term use of thalidomide led to an intense transient increase in T cell activation and inflamma-
tion, with a decrease in the CD4+ cell count without changes to the CD8+ cell count. We confirmed that thalid-
omide acts in vitro as a latency reversal agent and speculate that the in vivo results obtained were due to an
increase in HIV replication.6o andar
. This is a©2017 TheAuthors. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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HIV1. Introduction
Generalized immune activation and inflammation are hallmarks of
the pathogenesis of HIV/AIDS (d'Ettorre et al., 2011). Important factors, Vila Clementino, São
n open access article underdriving HIV-induced immune activation include ongoing viral replica-
tion, microbial translocation from the gastrointestinal (GI) tract and
co-infections (Marchetti et al., 2013). Irreversible damage to the integ-
rity of the GI tract's mucosal barrier occurs early during HIV-1 acute
infection caused by the irreversiblemassive depletion of CD4+ T (mem-
ory) cells from the GI tract mucosa, resulting in systemic activation of
the immune system via the translocation of GI tract microbes and lipo-
polysaccharide (LPS, as a marker of microbial translocation) across thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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can detect very low levels of detectable HIV RNA in rectal samples of
HIV-infected individuals with undetectable plasma viremia. Despite
being on antiretroviral therapy (ART), this ongoing low-level replication
at sites such as the GI tract contributes to the disease burden. During
ART, microbial translocation declines but does not return to normal
levels, indicating the potential role of microbial translocation in HIV-
induced immune activation (Palmer, 2013).
The HIV-induced dysregulation of CD4+ T regulatory (Treg) cells
also results in a permanently over-activated immune system due to
the lack of immunomodulation (Chevalier and Weiss, 2013). The over-
burden of viral gene products together with those of foreign pathogens
causes the overactivation of both T and B cells. The non-specific produc-
tion of pro-inflammatory cytokines, such as tumor necrosis factor alpha
(TNFα), interleukin-1 (IL-1), IL-6 and several others, causes the by-
stander activation of T and B lymphocytes and ultimately leads to
immunosenescence (Reeves, 2014). HIV-1 replication per se also relates
to immune activation, and the higher the viral load, the higher the im-
mune activation process (Hunt et al., 2003). It has been demonstrated
that even defective HIV may produce HIV proteins, which conceivably
maintains a state of inflammation in antiretroviral-suppressed individ-
uals (Imamichi et al., 2016). Interestingly, cell activation is higher
amongHIV-infected elite controllers than amonguninfected individuals
or antiretroviral-treated individuals with viral loads below detection
limits (Hunt et al., 2006).
This persistent immune activation and inflammation is responsible
for enhanced CD4+ T cell death, lymphoid tissue destruction, kidney
and liver problems, atherosclerosis, cardiovascular disease and
neurocognitive impairment (Reeves, 2014). Therefore, the future treat-
ment ofHIV/AIDS requires the consideration of anti-inflammatory strat-
egies with antivirals to overcome chronic inflammation-associated
complications.
HIV-related immune activation is associatedwith a rapid and persis-
tent increase in TNF levels (McMichael et al., 2010), resulting in the in-
duction of adhesion molecules and chemokines from the vessel wall
(Signorelli et al., 2007), endothelial cell activation and the increased ad-
hesion of leukocytes (Mu et al., 2007).
One of the drugs known for its immunomodulatory potential is
thalidomide.
Thalidomide has a beneficial effect on skin lesions of leprosy, erythe-
ma nodosum leprosum (Teo et al., 2002) and multiple myeloma (Chen
et al., 2010). Thalidomide is used in the treatment of various autoim-
mune or inflammatory disorders, such as Behçet disease, cutaneous
lupus erythematosus, prurigo nodularis, sarcoidosis, chronic graft-ver-
sus-host disease, and Kaposi's sarcoma (Chen et al., 2010; Franks et al.,
2004).
The pharmacological effects of thalidomide have established it as an
anti-inflammatory, immuno-modulatory and anti-angiogenic drug. The
mechanisms underlying these features involve the modulation of in-
flammatory cytokines, such as TNFα, interferon gamma (IFNγ), IL-10,
IL-12, cyclooxygenase 2 (COX-2) and nuclear factor kappa-light-chain-
enhancer of activated B cells (NFκB) (Franks et al., 2004).
The transcription factor NFκB controls the anti-inflammatory and
anti-angiogenic properties of thalidomide. NFκB is located in the
cytoplasm in its inactive form bound to the inhibitory protein IκBα.
Once stimulated by inducers such as TNF-α or IL-1β, the phosphoryla-
tion of IκBα proteins by IκB kinase (IKK) releases NFκB, which translo-
cates to the nucleus and induces the activation of genes responsible
for immune and inflammatory responses, cellular proliferation, angio-
genesis and the suppression of apoptosis (Wang et al., 1999). Thalido-
mide exerts its anti-inflammatory effect by enhancing the degradation
of TNF-αmRNA, as observed in endotoxin-stimulated monocytes and
macrophages (Moreira et al., 1993). In contrast to this anti-TNF activity
of thalidomide, IL-2-dependent upregulation of TNF-α by CD4+ and
CD8+ T lymphocytes has also been observed in vitro (Marriott et al.,
2002).NFκB is an enhancer of HIV-1 transcription, which, upon the
activation of an infected cell, migrates to the nucleus and induces the
expression of HIV-1 genes (Pomerantz et al., 1990). Because of the con-
vergence of the regulatory pathways for the transcription of HIV and of
cytokine genes, it is possible that interventions directed at limiting the
cytokine response to HIV-1 and opportunistic infections could have a
profound impact on the replicatingHIV-1 levels aswell as the associated
morbidity and mortality.
The link between circulating HIV and TNF-α (Klausner et al., 1996)
or TNF-α receptors (Bilello et al., 1996) has long been identified in
the plasma of infected individuals, and TNF-α induces viral replication
via a shared NFκB-dependent transcriptional control mechanism
(Pomerantz et al., 1990). Targeting TNF-αmay reduce viral replication,
resulting in lower inflammation. Thalidomide has shown promising re-
sults in inhibiting the production of TNF-α both in vitro and in vivo
(Sampaio et al., 1993). These observations have provided the rationale
for exploring the anti-inflammatory potential of thalidomide to inhibit
TNF-α, thereby reducing HIV replication and associated inflammation.
The present study was designed to examine whether thalidomide
treatment of HIV-1-infected individuals would reduce the levels of
HIV surrogate markers of inflammation. We recruited HIV-infected
individuals who had not undergone ART, in whom any potential anti-
inflammatory properties of thalidomide would be better quantified.
We treated these individuals for a period of 3 weeks with thalidomide
and followed the patients for 23 weeks. The results were compared to
those obtained in a control group consisting of ART-naïve individuals
who remained naïve throughout the study period.
Hypothesis. We hypothesized that the use of thalidomide would be
safe and able to decrease HIV-related inflammation and bacterial trans-
location. If this hypothesis is confirmed, new trials should include HIV
antiretroviral-treated individualswith viral loads belowdetection limits
to further explore the impact of anti-TNF drugs on HIV-1-related
inflammatory markers.2. Materials and Methods
2.1. Study Design and Participants
This was an open-label, randomised pilot proof-of-concept trial.
Thirty individuals were recruited in Rio de Janeiro, Brazil and followed
for 23 weeks from April 2011 to January 2013. The subjects were ran-
domly allocated into two groups: the Thalidomide group or Control
group (with no thalidomide exposure).
Patients were ART-naïve males from 18 to 60 years of age with a
body weight ≥50 kg and CD4+ T cell counts N350 cells/mm3. The partic-
ipants were not eligible to begin ART according to local guidelines for
the study period. (http://www.aids.gov.br/sites/default/files/consenso
Adulto005c_2008montado.pdf)
Informed consent forms were signed by the participants, and the
study protocol was approved by the Ethics Committee and Institutional
Review Board at the Universidade Federal de São Paulo, Brazil (#17686/
09) and Universidade Federal do Rio de Janeiro (#658/10).
2.2. Interventions
Patients were randomised to either receive 100 mg of thalidomide
BID for 3 weeks upon study entry (Thalidomide group, 16 patients) or
not (Control group, 14 patients); all were followed for 23 weeks.
Blood samples were collected for safety tests and HIV monitoring
tests, and laboratory work was performed at the Laboratório de
Retrovirologia of the Universidade Federal de São Paulo, Brazil. The
cell activation markers were double-checked at the Laboratório
Interdisciplinar de Pesquisas Médicas, Instituto Oswaldo Cruz/FIOCRUZ,
Rio de Janeiro, Brazil.
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As a pilot study, a convenience sample size of 30 patients was
determined.
2.4. Randomisation
Unrestricted randomisation. Allocation to distinct groups was deter-
mined using blind envelopes.
2.5. Clinical and Laboratory Assessments
Clinical and laboratory assessments were performed at the screen-
ing, baseline and at weeks 1, 2, 3, 7, 11, 15, 19, and 23. Patients were
evaluated for HIV-1 viral loads, CD4+ and CD8+ T cell counts, ultra-sen-
sitive C-reactive protein (US-CRP), CD38 and HLA-DR on CD4+ and
CD8+ T cells, and LPS quantitation in plasma samples. Blood cell counts
and biochemical parameters such as aminotransferase enzymes (ALT
and AST), creatinine, and glucose were determined at the screening
and at each visit. Electrocardiography was performed at the screening
and the last visit.
Clinical assessment included clinical signs and symptoms related to
HIV infection, adverse events, and adherence to thalidomide intake
using a predefined questionnaire.
2.6. Laboratory Methods
2.6.1. Flow Cytometric Evaluation of Cellular Activation
Peripheral blood mononuclear cells (PBMC) were separated and
cryopreserved. After thawing, PBMCs were labeled with anti-CD3 APC
and anti-CD4 PercP (for the lymphocytic subpopulation) and anti-
CD38 FITC and anti-HLA-DR PE (for cellular activation). Fixed cells
were acquired on a FACSCalibur apparatus and analyzedwith CellQuest
software (BD Biosciences, San Diego CA, USA). The results were
expressed as the percentage of CD38+HLA-DR+ cells among CD4+
and CD8+ T lymphocytes.Fig. 1. Participant2.6.2. Assessment of Plasmatic LPS Levels
Microbial translocation was inferred by plasmatic LPS assessments
using QCL-1000 Limulus Amebocyte Lysate (Lonza Walkersville Inc.,
Walkersville, MD, USA) according to the manufacturer's instructions.
The results were expressed as pg/mL, and the minimum limit of detec-
tion was 10 pg/mL.
2.6.3. Cytokine Measurement
Cytokine levelsweremeasured in plasma by Cytometric Beads Array
kit (CBA, BDBiosciences, SanDiego, CA, USA) processed according to the
manufacturer's protocol. The following cytokine were quantified: IL-2,
IL-4, IL-6, IL-10, IL-17, TNF and IFN-γ. A FACSCalibur were used to ac-
quire the samples and data analysis was performed using the software
provided by the manufacturer (FCAP Array, BD Biosciences). The stan-
dard curve for each cytokine covers a range of 20 to 5000 pg/mL.
2.6.4. Determination of CXCR4 and CCR5 Co-receptor Genotropism
After RNAextraction, reverse transcription nested PCR to amplify the
HIV-1 C2V3 region of gp120 and sequencing were carried out as
previously described (Lavigne et al., 2014). V3 loop sequences were
interpreted to infer co-receptor tropism by web-based genotyping
algorithms in Geno2pheno [coreceptor] (http://www.coreceptor.
geno2pheno.org). Because only one PCR product was subjected to se-
quencing, in accordance with European guidelines, a false positive rate
(FPR) of 10% was used to infer tropism (Poveda et al., 2012), and sam-
ples were classified as R5 (FPR N 10%) or non-R5 (FPR ≤ 10%) tropic.
2.6.5. In Vitro Determination of Thalidomide's Effect on the HIV-1 Proviral
Compartment
CD8+ T-cell depleted PBMCs (EasySep Human CD8 Positive Selec-
tion kit, STEMCELL TECHNOLOGIES) isolated from 7 HIV-infected ART-
treated patients with undetectable viral loads over a period of two
years were used. We measured HIV-1 recovery in ex vivo cell cultures
first activated by phytohemagglutinin and treated with thalidomide
(Sigma Aldrich) for 48 h and then cultured in RPMI medium (Gibco,
CA, USA) supplemented with IL-2 20 IU/mL (Roche) and fetal bovine's flowchart.
Table 2
Adverse events during the clinical trial period. No grade 3 and 4 adverse events were
detected.
Thalidomide group Week
1
Week
2
Week
3
Week
7
Week
15
Week
21
Week
23
N N N N N N N
Probably unrelated to
thalidomide
Syphilis 1 1
HPV 1
Possibly unrelated to
thalidomide
Diarrhea 1 1
Common cold
symptoms
3 2⁎ 2⁎ 1⁎
Infectious
gastroenteritis
1 1⁎
Sinusitis 1
Furunculosis 1
Intestinal constipation 1
Possibly related to
thalidomide
Somnolence 12 10 9
Skin rash 1
Dry mouth 1
Dry skin 1 1
Control group
Gingivitis 1 1⁎ 1⁎ 1⁎ 1⁎ 1⁎
Cold 1 1 1⁎
Dental abscess 1 1⁎
Tonsillitis 1
Syphilis 1
Gonorrhea 1
⁎ Patient presented the same symptoms at subsequent visit. N = number of patients.
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pernatant samples were taken at days 3, 7, 10, 14, 17, 21, 24, 28 and 31
and monitored by commercial HIV viral load assay (Abbott RealTime
HIV-1 assay, Abbott, Chicago IL).
2.7. Statistical Analyses
The Mann-Whitney U test, Student's t-test, analysis of variance
(ANOVA), and the Kruskal-Wallis test with Dunn's post hoc test were
used for comparisons between groups. Spearman's test was used to
perform correlations between different parameters. GraphPad Prism
version 5.0 for Windows (GraphPad Software, San Diego, CA, USA)
was employed for the analyses.
3. Results
3.1. Patients' Dispositions, Baseline Characteristics and Virologic/Immunolog-
ic Response to Therapy
The participant's Flow chart is described in Fig. 1. Thalidomide-treat-
ed patients and control patients were comparable in terms of age, T cell
counts and HIV viral load at the beginning of the study (Table 1). One
patient in the Thalidomide group was co-infected with HCV, and one
patient in the Control group was co-infected with HBV.
Adherence was measured weekly using a predefined questionnaire,
and the pill count indicated 100% thalidomide use. One patient stopped
themedication on day 16 due to amild cutaneous rash that disappeared
upon thalidomide interruption. There were no grade 3 or 4 adverse
events during thalidomide use (Table 2).Table 1
Baseline characteristics of the thalidomide and control groups.
Characteristics Thalidomide Control p-Value
N 16 14
Age (±SD) 36.88 (±9.28) 31.36 (±5.47) 0.16
Viral load log10
Mean (±SD) 3.67 (±1.33) 3.82 (±0.57) 0.59
Median 4.11 3.75
IQR 3.83–4.62 3.46–4.21
CD4+ T cells/mm3
Mean (±SD) 623 (±231) 605 (±255) 0.93
Median 602 625
IQR 468–660 388–716
CD8+ T cells/mm3
Mean (±SD) 1162 (±396) 1014 (±360) 0.57
Median 1117 1061
IQR 865–1383 734–1278
CD4/CD8 ratio
Mean (±SD) 0.58 (±0.23) 0.67 (±0.36) 0.77
Median 0.55 0.52
IQR 0.38–0.71 0.41–0.85
CD4/CD38/HLA-DR
Mean (±SD) 7.10 (±4.7) 5.98 (±3.42) 0.75
Median 5.64 5.68
IQR 2.82–12.1 3.18–7.36
CD8/CD38/HLA-DR
Mean (±SD) 20.41 (±13.6) 20.07 (±8.8) 0.93
Median 18.32 16.72
IQR 7.73–32.74 13.90–24.25
US-PCR mg/dL
Mean (±SD) 2.70 (±1.6) 2.15 (±1.09) 0.45
Median 2.72 2.03
IQR 1.34–4.28 1.21–3,07
LPS level pg/mL
Mean (±SD) 59.51 (±28,7) 46.59 (±21.7) 0.30
Median 51.05 42.9
IQR 35.15–79.03 30.70–66.70
B subtype
R5 8 11
Change of tropism 0/8 4/11Themean baseline viral loadswere 3.67 (range: b2.6–4.85) and 3.82
(range: 2.93–4.95) log10 HIV-1 RNA copies/mL for the Thalidomide and
Control groups, respectively (Table 1). A non-significant increase in viral
loadwas observed in Thalidomide group during the three weeks of tha-
lidomide therapy; the mean viral load increased from 3.67 to 3.83 log10
HIV-1 RNA copies/mL, returning to baseline values after thalidomide
withdrawal (Supplemental Table 1). At week 23, the mean viral loads
were 3.65 (range: b50–5.67) and 4.06 (range: 3.38–5.04) log10 copies/
mL for the Thalidomide and Control groups, respectively (Supplemental
Tables 1 and 2). One patient (TV13) in the Thalidomide group was an
elite controller, and at week 8, detectable viremia of 67 (1.83 log10)
copies/mL was observed, which returned to undetectable levels in sub-
sequent visits (Supplemental Table 1).
The screening mean CD4+ T cell count was 623 cells/mm3 ± 230
(median: 602 cells/mm3, IQR: 468–660 cells/mm3) and 605 cells/mm3
± 255 (median: 625 cells/mm3, IQR: 388–716 cells/mm3) for the
Thalidomide and Control groups, respectively. Declines in the CD4+ T
cell count (p = 0.04) and the CD4/CD8 ratio (p = 0.05) were observed
during thalidomide use in the Thalidomide group, returning to baseline
levels after drug withdrawal (Fig. 2) (Supplemental Tables 1 and 2).
During the study period, the CD4+ T cell count of four patients (TV03,
11, 29 and 31) in the Thalidomide group and one patient (TV12) in
the Control group declined to b350 cells/mm3 (were excluded from
the subsequent analysis, as they initiated ART (Fisher's exact test: p =
0.6)).
The overall screening mean CD8+ T cell counts were 1162 ±
396 cells/mm3 (median: 1117 cells/mm3, IQR: 865–1383 cells/mm3)
and 1014 ± 360 cells/mm3 (median: 1061 cells/mm3, IQR: 734–
1278 cells/mm3) for the Thalidomide and Control groups, respectively.
No significant change in the CD8+ T cell count was detected in either
group (Table 1, Supplemental Tables 1 and 2).
As seen in Fig. 3, the mean Leucocytes count in the Thalidomide
group was 6577.33 cells/mL as compared to 5402 cells/mL at week 23
(p = 0.03), and mean lymphocytes counts was 2283.79 cells/mL at
Fig. 2. Ratio of CD4+ T cell counts and CD4/CD8+ T cell counts over time among groups of Thalidomide and Control patients. Peripheral blood from patient of all groups was collected at
each visit during 24weeks for the absolute quantification of CD4+ andCD8+T lymphocytes byflow cytometry. The closed symbols relate to absolute CD4+ T cell counts, and open symbols
relate to the CD4/CD8+ ratio. The results are expressed as the mean ± standard deviation. N = number of participants.
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Leucocytes in the Control group were 5610.77 and 5653.08 cells/mL at
baseline and week 23 respectively (p = 0.9), and mean lymphocytes
counts were 1973.54 and 1009.92 cells/mL at baseline and week 23
respectively (p = 0.7).
3.2. Thalidomide was Accompanied by Increased Inflammation and Cell
Activation Levels
At study onset, the levels of CD4+- or CD8+-activated T lympho-
cytes, as inferred by the percentages of cells expressing CD38 and
HLA-DR, were similar in both groups, as shown in Table 1.
Counterintuitively, the Thalidomide group presented an increased
cell activation status inferred by the percentage of CD38+/HLA-DR+
CD4+ cells and the CD8+ T cell counts (p b 0.05). This analysis wasFig. 3. Leukocytes and Lymphocytes count at baseline and at the end of the study. Results are sho
C and D respectively), and statistical analysis was performed using Pared parametric t-test.repeated in the two participating laboratories at UNIFESP and FIOCRUZ,
and the results were consistent (Fig. 4). In the elite controller patient,
the percentage of CD38/HLA-DR+ on CD8+ cells increased during the
thalidomide period from 3.2% to 11.3% after 3 weeks of thalidomide
and then decreasing to 2.2, 2.4 and 1.8% at weeks 8, 12 and 20, respec-
tively. No activation of CD4+ T cells was observed (data on file).
Furthermore, an increase in the unspecific inflammatorymarker US-
CRP was also detected in the Thalidomide group exclusively during the
thalidomide intake period (Fig. 5, p= 0.004). All 30 enrolled volunteers
showed a US-CRP level above 0.1 mg/dL during the screening visit; this
levelwas above 1mg/dL in 88% of the Thalidomide group and 86% of the
Control group.
In relation to LPS levels, there was no significant baseline difference
between the Thalidomide group (mean: 59.5 ± 28.7 pg/mL) and Con-
trol group (mean: 46.6 ± 21.7 pg/mL). However, a non-staticallywn for the Thalidomide group (panels A and B respectively), and the control group (panels
Fig. 4. T cell activation status over time among the Thalidomide and Control groups. Peripheral blood mononuclear cells (PBMC) from patients of all groups were obtained by Ficoll-
Hypaque gradient centrifugation. PBMC were thawed and used for immunophenotyping at the pre-established periods over 24 weeks. The percentages of CD38+/HLA-DR+ CD4+ T
cells (2A) and CD8+ T cells (2B) are expressed as the mean ± standard deviation (Panel A) and median (Panel B). The Thalidomide group showed an increased cell activation status
compared to the Control group (p b 0.05). Thalidomide intake began in week 1 and was completed at the end of week 3. Patients were followed up until the end of week 23.
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group during thalidomide intakewith a reduction in the levels observed
at subsequent visits.3.2.1. Additional Correlations
There was also a positive correlation between T cell activation and
viral load, demonstrated in both the percentage of CD38/HLA-DR+
CD8+ cells and the CD4+ T cell counts in both the Thalidomide and Con-
trol groups (p= 0.001, Supplemental Fig. 1). Interestingly, the increase
in LPS level was accompanied by an increase in the US-CPR level in the
Thalidomide group (p= 0.05, Supplemental Fig. 2). Interestingly, there
was an apparent increase in the TNF levels in some individuals on the
Thalidomide arm as compared to the control arm when comparing
baseline levels to the levels encountered on the last day of Thalidomide
intake (Fig. 6). However, no statistical significance in themean andme-
dian TNF levels between different time points in each group. No statisti-
cal difference was detected in the other cytokine levels related to the
period of Thalidomide intake (data on file).Fig. 5. Inflammatory status over time in the Thalidomide group andControl group inferred
by the levels of ultra-sensitive C-reactive protein (US-CRP) were assessed in the patients
plasma by colorimetric assay. The levels are expressed as medians.3.3. HIV Evolution Vis a Vis Co-receptor Tropism
To understand the changes in the CD4+ T cell count during thalido-
mide therapy and the possible link with the HIV-1 subtype or co-recep-
tor used, co-receptor tropism was assessed from plasma RNA. Initially,
co-receptor tropism was assessed at screening and week 24. In case of
amplification failure and/or detection of non-R5 viruses, intermediate
collection time points were also analyzed. Amino acid alignments of
the HIV-1 envelope V3 loops along with their inferred viral tropism
and subtypes are shown in Supplemental Figs. 3 and 4. The co-receptor
tropismof both groups at successive visits is shown in Table 3. No signif-
icant differences were observed in either group in terms of viral load
and CD4+ and CD8+ T cell counts on the basis of the tropism profiles
(data on file).
As shown in Table 3, a change/switch in co-receptor tropismwas not
observed in 7 individuals in the Thalidomide groupharboring R5 viruses
at thefinal visit of the study period. However, in the Control group, 3 out
of 12 patients switched to using CXCR4 during the study period (Fisher
exact test, p=0.2). HIV-1 subtypes and the co-receptor tropismprofiles
of the individuals were not found to influence the changes in CD4+ T
cell counts observed in our study. The observed changes in CD4+ T
cell counts were therefore an effect of thalidomide therapy (Table 3).
3.4. The In Vitro Effect of Thalidomide on HIV-infected Cells
The altered laboratory values detected in the Thalidomide group
returned to baseline levels after thalidomide withdrawal. Although
safe, the short-term use of thalidomide among ART-naïve individuals
led to a counter-intuitive intense transitory increase in T cell activation
and inflammation, with a decrease in CD4+ T cells without a detectable
change in CD8+ T cells and viral loads, although it is inherently difficult
to detect changes in viral load among naturally viremic individuals. We
therefore asked whether these results might be related to the potential
purging activity of thalidomide.
Samples from 7 individuals not participating in this study and under
ART with viral loads below the detection limits for a mean period of
Fig. 6. Levels of TNF in the Thalidomide arm and control arm. Despite the apparent increase in the TNF levels in some individuals on the Thalidomide arm as compared to the control arm
when comparingbaseline levels to the levels encountered on the last day of Thalidomide intake, no statistical significance in themean andmedian TNF levels between different time points
in each group was observed.
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pleted of other PBMCswere used. Thalidomide treatment induced purg-
ing in 6 out of 7 samples (Fig. 7). On the secondday after treatmentwith
thalidomide, the culture supernatants were tested for viral load using
qPCR, and the results revealed HIV-1 emergence at day 4 with a change
in viral load from 2.2 log10 to 6.0 log10 (median of 5.7 log10) HIV-1 RNA
copies/mL, whereas viruses were not detected in control samples
(Table 4). Relating viral emergence with clinical parameters showed
that culture positivity was independent of the CD4+ T cell nadir, the
time of viral load below detection limits, the antiretroviral scheme,
viral tropism and the subtype of virus (data on file), reinforcing the
role of thalidomide in this phenomenon.
4. Discussion
In this study, we explored the effects of thalidomide among ART-
naïve HIV-infected individuals with stable CD4+ T cell levels for the
short period of three weeks in comparison to an equivalent control
group, both to be followed by a period of 23 weeks. As a potent TNF-α
inhibitor, our hypothesis was that thalidomide use would be safe andTable 3
HIV-1 and V3 co-receptor tropism of the Thalidomide group at successive visits inferred throu
receptor tropism not determined.
ID Screening Baseline Week 1 Week 2
Thalidomide TV01 R5 R5 – –
TV03 – X4 – –
TV05 – – – –
TV07 R5 R5 – –
TV09 – R5 R5 R5
TV11 R5 R5 – –
TV13 – – – –
TV15 – – – –
TV21 R5 R5 – –
TV23 R5 R5 – –
TV25 R5 R5 – –
TV27 – – – –
TV29 – – – –
TV31 R5 R5 – –
TV33 – X4 X4 X4
TV37 – – – –
Control TV02 – – R5 R5
TV06 – – R5 R5
TV08 – – X4 X4
TV12 – R5 – –
TV14 – X4 – X4
TV16 – R5 – –
TV18 – R5 – –
TV20 R5 R5 – –
TV22 R5 R5 R5 R5
TV24 R5 R5 – –
TV28 R5 R5 – –
TV32 R5 R5 X4 –
TV34 R5 R5 – –
TV36 R5 R5 – –able to mitigate one of the major changes associated with chronic HIV
infection: HIV-related inflammation. We also hypothesized that in the
absence of antiretroviral medications, the anti-inflammatory thalido-
mide effect would become more evident. Thus, we carefully monitored
HIV-related inflammatory markers, such as T cell activation, unspecific
inflammatory markers, such as US-CRP, and bacterial translocation
markers, such as plasmatic LPS levels, in addition to viral loads and
CD4+ and CD8+ T cell counts.
The basis of our hypothesis in this study was that TNF-α can trigger
the cytokine production cascade by inducing cytokine secretion by tar-
get cells. TNF-α acts by activating the cellular transcription factor NF-kB,
which induces the expression of cytokines and other cellular genes
(Breen, 2002). TNF-α can bind to two membrane receptors on target
cells, TNF receptor 1 (TNFR1, also known as TNFRSF1A and p55) or
TNF receptor 2 (TNFR2, also known as TNFRSF1B and p75), to activate
two distinct intracellular signaling pathways for gene transcription
(Faustman and Davis, 2010). TNFR1 is present in almost all cells of the
body, and its signaling induces the cascade related to apoptosis. TNF
binding to TNFR1 activates apoptosis through two pathways involving
the adaptor proteins TNFR1-associated death domain (TRADD) andgh Geno2pheno with an FPR set at 10%. -: HIV-1 env V3 region amplification failed or co-
Week 3 Week 7 Week 11 Week 17 Week 19 Week 23
– – – – – –
– – – – – X4
– – – – – –
– – – – – R5
– – R5 R5 R5 R5
– – – – – R5
– – – – – –
– – – – – –
– – – – – R5
– – – – – R5
– – – – – R5
– – – – X4 X4
– – – – – –
– – – – R5 –
X4 X4 X4 X4 – X4
– – – – – R5
R5 R5 R5 – – R5
R5 R5 R5 X4 – X4
X4 X4 X4 R5 X4 X4
– – R5 – – –
X4 X4 X4 – X4 –
– – R5 – R5 –
– – – – – R5
– – – – – R5
R5 R5 R5 X4 – X4
– – – – – R5
– – – – – R5
R5 R5 X4 – X4 X4
– – – – – R5
– – – – – R5
Fig. 7. The in vitro effect of Thalidomide on increase in viral load from PBMCs samples from seven patients on undetectable viral load. PBMCs were activated with Thalidomide in the
presence of Phytohaemagglutinin and IL-2 for 48 h. Viral RNA was quantified by qPCR. Y-axis shows HIV-1 RNA (log10 copies/ml). X-axis shows the days at which supernatants were
collected for viral RNA quantification. Symbol TA indicates patient ID.
66 T.R.C. Vergara et al. / EBioMedicine 23 (2017) 59–67Fas-associated death domain (FADD). TNFR2 is related to T cell survival,
and its signaling involves the mobilization of the transcription factor
NF-kB to promote the transcription of pro-survival genes. NF-κB con-
tributes to a variety of components of the immune system through its
role in the development and differentiation of immune cells and
lymphoid organs. NF-κB's strongest inducers are the cytokines TNF
and IL-1, as well as pathogen-derived LPS.
Surprisingly, however, we were able to document that T cell activa-
tion markedly increased in both CD4+ and CD8+ T cells during thalido-
mide exposure, returning to basal levels right after thalidomide
withdrawal, whereas no specific trends were detected in the control
group. The same result was observed in the Thalidomide groupwith re-
gard to the US-CPR level. Furthermore, the CD4+ T cell counts decreased
during thalidomide use without any changes in the CD8+ T cell counts,
leading to a decrease in the CD4/CD8 ratios, although these levels
returned to the baseline ranges immediately following thalidomide
withdrawal, thus confirming that these changes were exclusively relat-
ed to drug exposure. Again, no trends were observed in the control
group. Interestingly, no changes in the viral loads were observed in
both groups, and no changes were observed in the LPS plasma levels.
We then speculated that an HIV viral replication process could be trig-
gered by thalidomide, leading to an increase in inflammation and the
death of infected CD4+ T cells without any apparent disturbance of
CD8+ T cells and without changing the HIV-associated translocation
process. As the studied individuals were naturally viremic, we were
not able to detect any increase in the viral load levels because untreated
individuals are able to produce and eliminate 10 billion HIV virions
every day (Ho et al., 1995). However, previous studies using Thalido-
mide among HIV infected individuals have demonstrated a trend in
the increase of HIV viral load after Thalidomide exposure, when this
drug was used for oral aphthous ulcers (Jacobson et al., 1999) and HIV
wasting syndrome (Kaplan et al., 2000). In another placebo controlled
study, 28 days of thalidomide treatment was associated with the mod-
est overshoot in the rebound of viremia, which vanished after stoppingTable 4
Viral load in the culture supernatants from thalidomide-treated samples. Subjects with viral re
(copies/mL); BDL = Viral load below detection limits.
ID Day VL Day VL Day
TA1 0 b50 4 459 7
TA2 0 b50 4 3740 7
TA3 0 b50 4 522 7
TA4 0 b50 4 478 7
TA5 0 b50 4 6009 7
TA6 0 b50 4 BDL 7
TA7 0 b50 4 4191 7the drug (Haslett et al., 1999). Interestingly, one of the individuals re-
cruited in the Thalidomide groupwas an elite controller, andwe detect-
ed increased expression of T cell activation markers and an increase in
the US-CRP level during thalidomide use followed by a blip of viremia
to 67 (1.83 log10) copies/mL. We therefore conducted in vitro assays to
confirm that thalidomide was able to transactivate HIV, by showing
that this drug could act as a latency reversal agent. Surprisingly, our pre-
liminary results were unequivocal, showing a very potent latency-
reverting effect of thalidomide in samples from 6 out of 7 tested pa-
tients. Thalidomide has been associatedwith inhibition of NF-kB activity
through a mechanism that involves the suppression of Inhibitor of
kappa kinase (IKK) activity (Keifer et al., 2001). Since kappa kinase can-
not phosphorylate the inhibitor, NFKB stays arrested in the cytoplasm
and cell activation is halted at this step, which is the allegedmechanism
for the anti-inflammatory properties usually seen with Thalidomide
(Keifer et al., 2001). For complete T-cell activation, two signals delivered
by antigen presenting cells are required: (i) T cell receptor binding to its
cognate antigen and (ii) a co-stimulation signal inwhich CD28molecule
expressed by T cell bindswith CD80/86molecules expressed byAntigen
presenting Cells. Beside suppression of IKK, Thalidomide is also known
to co-stimulate T-cells via CD28 receptor (Haslett et al., 1998). This
effect of Thalidomide could be associated with T-cell activation and in-
crease in HIV replication, which reconciles with our in vivo and ex-vivo
results. In fact, HIV viral load increase has been previously reported
upon thalidomide therapy in trials treating oral aphthous ulcers
(Jacobson et al., 1999) and HIV wasting syndrome (Kaplan et al.,
2000). In another placebo controlled study, 28 days of thalidomide
treatment was also associated with the modest overshoot in the re-
bound of HIV viremia, which vanished after stopping the drug (Haslett
et al., 1999).
In spite of its inflammatory properties, TNF-α production can be a
restrictive factor for HIV replication, and it is conceivable that thalido-
mide use was able to block this process. TNF-α is detected after HIV-1
infection of primary macrophages in vitro and is present in plasma andbound after drug treatment are highlighted. C = Supernatant collection; VL = Viral load
VL Day VL Day VL
462 11 1378169 14 8469592
13,091 11 N10,000,000 14 N10,000,000
318 11 BDL 14 BDL
BDL 11 BDL 14 BDL
1685 11 1230 14 1047
BDL 11 BDL 14 BDL
1992 11 6610 14 71792
67T.R.C. Vergara et al. / EBioMedicine 23 (2017) 59–67tissues of patients with AIDS (Herbein et al., 1996). In vitro, TNF-α is
secreted by primary macrophages infected in culture by HIV-1 or treat-
ed with envelope glycoprotein gp120 and by HIV-infected monocytes
isolated from patients (Merrill et al., 1989). TNF-α is able to enhance
host cellular resistance to HIV-1 infection through selective inhibition
of HIV-1 entry into primary tissue culture-differentiated macrophages
(Herbein et al., 1996). One plausible strategy for the inhibition of HIV
entry by TNF-α in macrophages may be through negative modulation
of the transcription of CD4andCCR5,whichmight explain the inhibition
of HIV entry in these permissive cells (Karsten et al., 1996). For this rea-
son, we also monitored the ability of thalidomide to select CXCR4, al-
though no positive results were obtained in the current study. Of note
and as mentioned before, we have not been able to find any difference
in the cytokine levels between groups or during Thalidomide intake.
Interestingly, we observed in the Control group that T cell activation
slightly and linearly increased over time, even with no changes in the
basal viral loads. As seen in other studies, there was a positive correla-
tion between the viral loads and CD4 and CD8 T cell activation levels
(Hunt et al., 2003).
We recognize that the pilot proof-of-concept open-label nature of
this study, specifically related to the small sample size of recruited pa-
tients, may preclude conclusions that are more definite. Furthermore,
the lack of cytokine profile analysis also prevents us from further under-
standing the mechanisms related to the inflammatory processes
documented here. In addition, a comparison group of HIV-uninfected
individuals using thalidomide for the same period of timewould enable
us to further address the specific effects of thalidomide in association to
HIV. Nevertheless, our results clearly demonstrated that thalidomide in-
duces a potent inflammatory profile in the presence of HIV, indicating
that this drug may serve as an HIV purging tool in the new era of HIV-
sterilizing treatment discoveries.
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